+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Gemcitabine HCL Market Report and Forecast 2023-2031

  • PDF Icon

    Report

  • 147 Pages
  • May 2023
  • Region: Global
  • Expert Market Research
  • ID: 5797890
The global Gemcitabine HCl market value was USD 669.7 million in 2022, driven by the increasing prevalence of cancer across the globe. The market size is anticipated to grow at a CAGR of 7.4% during the forecast period of 2023-2031 to achieve a value of USD 1274.9 million by 2031.

Gemcitabine HCl Introduction

Gemcitabine HCl is a chemotherapy drug used to treat several types of cancer, including pancreatic cancer, breast cancer, non-small cell lung cancer, and bladder cancer. It is an antimetabolite drug that works by blocking the growth and spread of cancer cells in the body.

The global gemcitabine HCl market is driven by factors such as the increasing prevalence of cancer worldwide, rising demand for chemotherapy drugs, and the introduction of advanced technologies for the production of drugs. However, the high cost of gemcitabine HCl treatment and the risk of side effects associated with chemotherapy drugs are likely to hamper the growth of the market.

North America dominates the gemcitabine HCl market, followed by Europe and Asia Pacific. The increasing number of cancer patients and the availability of advanced healthcare infrastructure in developed countries such as the US and Canada are driving the growth of the market in North America.

In Asia Pacific, the market is expected to grow at a significant rate due to the increasing prevalence of cancer and the rising demand for chemotherapy drugs. Moreover, the presence of a large patient pool and the increasing focus of major market players on expanding their presence in the region are also contributing to the growth of the market.

Overall, the global gemcitabine HCl market is expected to grow in the coming years due to the increasing prevalence of cancer and the rising demand for chemotherapy drugs, especially in emerging economies.

Gemcitabine HCl Market Scenario

Gemcitabine HCl is a chemotherapy drug that is used to treat various types of cancer such as pancreatic, bladder, breast, lung, and ovarian cancer. It is administered through injection into a vein and works by slowing or stopping the growth of cancer cells.

The market for Gemcitabine HCl is driven by the increasing prevalence of cancer globally, as well as the rising demand for effective chemotherapy drugs. Additionally, the growing awareness about the benefits of early cancer detection and treatment is also contributing to the growth of the market.

However, the high cost of chemotherapy drugs and the availability of alternative treatments such as immunotherapy and targeted therapy may hinder the growth of the market to some extent.

Overall, the Gemcitabine HCl market is expected to experience significant growth in the coming years due to the increasing prevalence of cancer and the ongoing development of new and improved chemotherapy drugs.

Gemcitabine HCl Market Segmentations

Market Breakup by Type

  • Branded
  • Generics

Market Breakup by Indications

  • Breast Cancer
  • Non-Small Cell Lung Cancer
  • Ovarian Cancer
  • Pancreatic Cancer
  • Bladder Cancer
  • Biliary Tract Cancer
  • Others

Market Breakup by End User

  • Hospitals
  • Homecare
  • Specialty Centers
  • Others

Market Breakup by Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • Others

Market Breakup by Region

North America

  • United States of America
  • Canada

Europe

  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Key Trends in the Gemcitabine HCl Market

Some of the key trends in the Gemcitabine HCl market are:
  • Growing demand for cancer therapeutics: Gemcitabine HCl is primarily used for the treatment of various types of cancer, including pancreatic, lung, bladder, and breast cancers. With the growing incidence of cancer worldwide, the demand for cancer therapeutics such as Gemcitabine HCl is increasing
  • Rising focus on research and development: Leading players in the market are investing heavily in research and development activities to develop new and innovative products that can offer better patient outcomes. This has resulted in the launch of new formulations of Gemcitabine HCl, such as liposomal formulations
  • Increasing preference for combination therapy: In recent years, there has been a shift towards the use of combination therapy for the treatment of cancer. Gemcitabine HCl is often used in combination with other chemotherapeutic agents, such as cisplatin and carboplatin, to improve treatment outcomes
  • Growing popularity of generic versions: Generic versions of Gemcitabine HCl have gained significant popularity in recent years, owing to their lower cost as compared to branded versions. This has led to increased competition in the market, resulting in lower prices of the drug
  • Increasing adoption of Gemcitabine HCl in emerging economies: With the rising incidence of cancer in emerging economies such as India and China, the demand for Gemcitabine HCl is increasing in these regions. This presents significant growth opportunities for market players operating in these regions

Gemcitabine HCl Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • Pfizer Inc
  • F. Hoffmann-La Roche Ltd
  • Mylan N.V
  • Fresenius Kabi AG
  • Hebei Changshan Biochemical Pharmaceutical Co. Ltd
  • Hikma Pharmaceuticals PLC
  • Novartis AG
  • Shanghai Fosun Pharmaceutical (Group) Co., Ltd
  • Teva Pharmaceutical Industries Ltd
  • HEYER Medical AG
  • Biometrix
  • Smith’s Medical

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Gemcitabine HCl Market Overview
3.1 Global Gemcitabine HCl Market Historical Value (2016-2022)
3.2 Global Gemcitabine HCl Market Forecast Value (2023-2031)
4 Global Gemcitabine HCl Market Landscape
4.1 Global Gemcitabine HCl Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Gemcitabine HCl Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Applications
4.2.3 Analysis by Classifications
5 Global Gemcitabine HCl Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Gemcitabine HCl Market Segmentation
6.1 Global Gemcitabine HCl Market by Type
6.1.1 Market Overview
6.1.2 Branded
6.1.3 Generics
6.2 Global Gemcitabine HCl Market by Indications
6.2.1 Market Overview
6.2.2 Breast Cancer
6.2.3 Non-Small Cell Lung Cancer
6.2.4 Ovarian Cancer
6.2.5 Pancreatic Cancer
6.2.6 Bladder Cancer
6.2.7 Biliary Tract Cancer
6.2.8 Others
6.3 Global Gemcitabine HCl Market by End User
6.3.1 Market Overview
6.3.2 Hospitals
6.3.3 Homecare
6.3.4 Specialty Centers
6.3.5 Others
6.4 Global Gemcitabine HCl Market by Distribution Channel
6.4.1 Market Overview
6.4.2 Hospital Pharmacy
6.4.3 Online Pharmacy
6.4.4 Retail Pharmacy
6.4.5 Others
6.5 Global Gemcitabine HCl Market by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Gemcitabine HCl Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Gemcitabine HCl Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Gemcitabine HCl Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Gemcitabine HCl Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Gemcitabine HCl Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 Pfizer Inc.
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 F. Hoffmann-La Roche Ltd.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Mylan N.V.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Fresenius Kabi AG
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Hebei Changshan Biochemical Pharmaceutical Co. Ltd.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Hikma Pharmaceuticals PLC
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Novartis AG
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Shanghai Fosun Pharmaceutical (Group) Co., Ltd
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Teva Pharmaceutical Industries Ltd.
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 HEYER Medical AG
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Biometrix
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Smith’s Medical
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
18 Global Gemcitabine HCl Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket

Companies Mentioned

  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Fresenius Kabi AG
  • Hebei Changshan Biochemical Pharmaceutical Co. Ltd.
  • Hikma Pharmaceuticals plc
  • Novartis AG
  • Shanghai Fosun Pharmaceutical (Group) Co. Ltd
  • Teva Pharmaceutical Industries Ltd.
  • Heyer Medical AG
  • Biometrix
  • Smith’S Medical

Methodology

Loading
LOADING...

Table Information